Drugs / SGT-53
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07017816 | Dec 2025 → May 2028 expected | atypical teratoid rhabdoid tumor, ependymoma, malignant glioma, medulloblastoma +1 | Children's National Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT03554707 | Jun 2022 | central nervous system cancer | SynerGene Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 13 trials | ||||||
| Phase 1 | NCT05093387 | Nov 2022 | inflammatory breast carcinoma, triple-negative breast carcinoma | Northwestern University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02354547 | Dec 2014 → Dec 2027 | neoplasm | SynerGene Therapeutics, Inc. | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00470613 | Feb 2008 → Dec 2016 | neoplasm | SynerGene Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02340117 | Jan 2015 → Dec 2026 expected | malignant pancreatic neoplasm | SynerGene Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02340156 | Dec 2014 → Nov 2018 | glioblastoma | SynerGene Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGT-53 | “SGT-53 is a gene therapy that changes the deoxyribonucleic acid (DNA) of patients' tumor cells to make it easier for the immune system to recognize them.” NCT05093387 ↗ |
| Action | Restore | “Introduction of the p53 cDNA sequence is expected to restore wtp53 function in the apoptotic pathway.” NCT02340117 ↗ |
| Modality | Other / unclassified | “SGT-53 is a complex of cationic liposome encapsulating a normal human wild type p53 DNA sequence in a plasmid backbone.” NCT02340117 ↗ |
| Route | Other | “SGT-53 (2.4 mg DNA per infusion) will be administered” NCT00470613 ↗ |
| Target | TP53 | “SGT-53 is a complex composed of a wild type p53 gene (plasmid DNA)” NCT00470613 ↗ |